Bristol Myers Squibb
Bristol Myers Squibb is one of the most important commercial cell therapy developers globally, with approved CAR-T therapies in hematologic malignancies and a major presence in multiple myeloma and lymphoma. Its cell therapy platform was significantly strengthened through its acquisition of Celgene, which brought key cellular therapy assets and infrastructure.
- Highest 2026 tier: Tier I
- Cell & Gene Therapy Developers
- 3 ranking categories
Overview
Bristol Myers Squibb is one of the most important commercial cell therapy developers globally, with approved CAR-T therapies in hematologic malignancies and a major presence in multiple myeloma and lymphoma. Its cell therapy platform was significantly strengthened through its acquisition of Celgene, which brought key cellular therapy assets and infrastructure.
BMS’s strength lies in hematology and oncology depth. Cell therapy adoption is closely tied to specialist oncology networks, academic cancer centers, referral pathways, and toxicity-management expertise. BMS has strong relationships across these areas and a broad oncology portfolio that complements its cell therapy business.
Bristol Myers Squibb is included in 3 2026 ranking categories. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Bristol Myers Squibb |
| Founded | 1887 |
| Institution type | Cell & Gene Therapy Developers institution |
| Headquarters | Princeton, United States |
| Primary focus | Cell & Gene Therapy Developers |
| Highest 2026 ranking tier | Tier I |
Principal activities
BMS’s strength lies in hematology and oncology depth. Cell therapy adoption is closely tied to specialist oncology networks, academic cancer centers, referral pathways, and toxicity-management expertise. BMS has strong relationships across these areas and a broad oncology portfolio that complements its cell therapy business.
Core capability
Cell & Gene Therapy Developers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Cell & Gene Therapy Developers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Bristol Myers Squibb’s approved cell therapy portfolio, hematology presence, commercial infrastructure, and oncology pipeline support its position among the leading cell and gene therapy developers.
Bristol Myers Squibb is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Bristol Myers Squibb should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Bristol Myers Squibb. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Bristol Myers Squibb |
| Headquarters | Princeton, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Cell & Gene Therapy Developers 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Global Pharmaceutical Companies 2026 — 2026 inclusion and tier classification.
- Healthcare Ranking — Top 30 Vaccine & Immunotherapy Developers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
